Arnd Nusch

Ratingen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL.

Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL.

Journal: ESMO real world data and digital oncology

Published: April 20, 2026

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 04, 2025

Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registry.

Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registry.

Journal: Annals of hematology

Published: November 10, 2025

Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315).

Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315).

Journal: International journal of cancer

Published: August 26, 2025

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Journal: International journal of cancer

Published: August 06, 2025

Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry.

Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry.

Journal: ESMO real world data and digital oncology

Published: December 19, 2024

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study.

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study.

Journal: Leukemia & lymphoma

Published: December 10, 2024

Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.

Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.

Journal: International journal of cancer

Published: December 03, 2024

Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Journal: International journal of cancer

Published: July 31, 2024

Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.

Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 10, 2023

Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.

Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 27, 2023

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Journal: Breast cancer research : BCR

Published: January 10, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026